Canine Parvovirus Monoclonal Antibody
Canine Parvovirus Monoclonal Antibody
CPMA (now Trutect™) is the first and only monoclonal antibody (mAb) treatment that targets canine parvovirus (CPV) and has been shown to be effective for passive immunity (i.e. Parvovirus Prophylaxis) in puppies (8+weeks). CPMA helps provide quicker recovery for dogs and a better treatment experience for shelters.1
9/10 satisfaction rating2
83% of current users recommend to other vets2
Less doctor and staff time needed when incorporated into protocols2
Targeted Efficacy3
After challenged with virulent CPV-2b, zero dogs died when treated with Canine Parvovirus Monoclonal Antibody.
Why choose Canine Parvovirus Monoclonal Antibody?
We anticipate Canine Parvovirus Monoclonal Antibody will help greatly decrease the burden of supportive care for CPV. You may be able to save days of labor and stress associated with managing the symptoms of this potentially deadly disease.1,2
mAb that targets parvovirus directly
Single-dose efficacy
High safety profile
May help decrease burden of supportive care and may help reduce emotional stress
Check Out These CPMA Resources for Shelters
Order Now
For Immediate Orders: Call 1-800-782-8977
(Select option 2 and then option 2 again) OR
Email: elancovet@elancoah.com
Paws4Purpose
Participating in the Paws 4 Purpose program is an easy way to help your organization reach and maintain the high standards of disease prevention, diagnosis and treatment outlined in the Five Freedoms for Animal Welfare. You’ll also receive expert support, training resources, access to continuing education content and trusted quality products, including CPMA.
To learn more contact your Elanco Sales Representative.
1Welton et al. 2024 ABVP Abstracts.
2Elanco Animal Health. Market Data on File.
3Larson L et al. J Am Vet Med Assoc. 2024;262:506-512.
